We are live on ! Find out more
ERNA icon

Eterna Therapeutics
ERNA

10 hedge funds and large institutions have $750K invested in Eterna Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 10 → 10 (0)

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

34% less capital invested

Capital invested by funds: $1.14M → $750K (-$385K)

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$30.3K
2
SCA
Sippican Capital Advisors
Massachusetts
+$22.2K
3
TRCT
Tower Research Capital (TRC)
New York
+$13.1K
4
NW
Naviter Wealth
Arkansas
+$2.02K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$44K
2
BlackRock
BlackRock
New York
-$15.1K
3
UBS Group
UBS Group
Switzerland
-$13.1K
4
Corient Private Wealth
Corient Private Wealth
Florida
-$2.02K
5
Bank of America
Bank of America
North Carolina
-$31
Name Holding Trade Value Shares
Change 		Change in
Stake
CPWM
1
Cypress Point Wealth Management
Texas
$213K – – –
NW
2
Naviter Wealth
Arkansas
$182K +$2.02K +2 +0.9%
Corient Private Wealth
3
Corient Private Wealth
Florida
$134K -$2.02K -2 -1%
SCA
4
Sippican Capital Advisors
Massachusetts
$48.8K +$22.2K +22 +61%
Vanguard Group
5
Vanguard Group
Pennsylvania
$43.1K – – –
BlackRock
6
BlackRock
New York
$40.2K -$15.1K -15 -24%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$30.4K – – –
Goldman Sachs
8
Goldman Sachs
New York
$25.5K +$30.3K +30 New
BWP
9
Baldwin Wealth Partners
Massachusetts
$21.4K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$11.4K +$13.1K +13 New
CHA
11
Carmichael Hill & Associates
Maryland
$170 – – –
MA
12
Montag & Associates
Georgia
$159 – – –
Morgan Stanley
13
Morgan Stanley
New York
$113 – – –
Wells Fargo
14
Wells Fargo
California
$75 – – –
Group One Trading
15
Group One Trading
Illinois
$42 – – –
Citigroup
16
Citigroup
New York
$33 – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$31 – – –
APC
18
Aspire Private Capital
North Carolina
$23 – – –
Fidelity Investments
19
Fidelity Investments
Massachusetts
$2 – – –
Renaissance Technologies
20
Renaissance Technologies
New York
– -$44K -35 Closed
UBS Group
21
UBS Group
Switzerland
– -$13.1K -10 Closed
Bank of America
22
Bank of America
North Carolina
– -$31 – –

ERNA Hedge Fund Activity: Q2 2023 in Review

10 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2023, worth a combined $750K — down 34% from $1.14M a quarter earlier.

Fund positioning in ERNA was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 2 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $30.3K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $44K sold.

  • 10 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $750K of Eterna Therapeutics stock for Q2 2023, down 34% quarter-over-quarter.
  • 2 funds opened new Eterna Therapeutics positions in Q2 2023 and 2 closed out, a net change of 0 holders.
  • The largest Eterna Therapeutics buyer in Q2 2023 was Goldman Sachs, an estimated $30.3K added.
  • The largest Eterna Therapeutics seller in Q2 2023 was Renaissance Technologies, an estimated $44K sold.

Based on aggregated 13F filings for Q2 2023.